Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

An update on psychopharmacological treatment of Body Dysmorphic Disorder (BDD)

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Anorexia Nervosa and Motivation for Behavioral Change - Can it be Enhanced?

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. A Brief Review of the Biology of Anorexia Nervosa

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. The Diagnostic Work-Up of Eating Disorders

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Case report: cognitive performance in an extreme case of anorexia nervosa with a body mass index of 7.7

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Slime-loving bacteria from fresh faeces may be able to help anorexia patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelFormidling

  3. Hvorfor fravælger halvdelen behandling for en spiseforstyrrelse?

    Publikation: Bidrag til tidsskriftBidrag til avis - AvisartikelFormidling

  4. On motivation as a Target for Intervention in Anorexia Nervosa

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. A systematic review of blood-based serotonergic biomarker in Bulimia Nervosa

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
Background: Body Dysmorphic Disorder (BDD) is a common, often severe disorder
characterized by appearance concerns and a preoccupation with thinking and behaviors
related to this concern. Population-based investigations have found a prevalence of BDD of
1.5-2% in the general population. The first-line of treatment for BDD is usually Selective
Serotonin Reuptake Inhibitors (SSRI) which often alleviates suicidal thinking, and act
to protect against further aggravation of suicidal thinking. For delusions, antipsychotic
treatment is usually required. This review provides an update on guidelines and
pharmacological treatment studies of BDD including recommendations for management
and treatment.
Material and method: A narrative review of the current literature.
Results: A presentation of guidelines, some key studies and recommendations for
pharmacological treatment of BDD.
Conclusion: Only one placebo controlled efficacy trial has been done finding that fluoxetin
is superior to placebo in treatment of BDD. Several open trials support this finding and a
randomized trial have found SSRI to reduce time to relapse. Clinical experiences suggest
SSRI may reduce risk of suicidality. In severe cases, add-on treatment of second generation
anti-psychotics may alleviate psychotic symptoms.
OriginalsprogEngelsk
TidsskriftJournal of Psychology and Clinical Psychiatry
Vol/bind10
Udgave nummer6
Sider (fra-til)228-232
Antal sider5
ISSN2373-6445
DOI
StatusUdgivet - 25 nov. 2019

ID: 59087073